ImmunoCellular Investor Presentation

•

3 recomendaciones•448 vistas

IMUC is a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

Empresariales Tecnología

January 2010 Manish Singh, PhD President and CEO OTC BB: IMUC.OB www.imuc.com

SEC Disclaimer Statement ,[object Object],January 2010

Cancer Stem Cells: Good Guys Turned Bad ,[object Object],[object Object],January 2010 Targeting CSCs may significantly delay or prevent disease recurrences. Normal Stem Cell mutations Cancer Stem Cell Mature Tissue Bulk Tumor Progenitor cells

Technology Overview: Utilizing Both Arms of Immune System ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

ICT-107: Dendritic Cell-Based Vaccine Targeting Cancer Stem Cells and Tumor Associated Antigens January 2010 Antigens Tumor Expression CSC Expression gp100 Melanoma, brain cancer Trp-2 Melanoma and brain cancer High Her-2/neu Breast, ovarian cancer Medium MAGE-1 Melanoma, brain cancer AIM Breast, ovarian, colon, brain High IL-13aR2 Brain cancer

January 2010 Significant Improvement in Progression-Free Survival (Compared to Historical Controls Using Standard of Care) Radiation + Temozolomide* Radiation + Temozolomide +ICT-107 ,[object Object],[object Object]

Summary of Clinical Data: Progression-Free and Overall Survival January 2010 SOC = Standard of care (surgery + radiation + Temozolomide) Newly Diagnosed (16) SOC + ICT-107 Historical Control (SOC) Median PFS (months) 19.0 6.9 Median OS (months) > 21 14.2 % Survival at 12 months 94% 60% % Survival at 21 months 80% 30% Recurrent (3) Median OS (months) 30.5 7.0 (9.2 with Avastin+SOC)

ICT-121: Cancer Stem Cell Vaccine ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010 Potential Blockbuster Product

Summary of Antibody Programs January 2010 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Value Creation Catalysts in Next 12 Months ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Management Team ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Key Opinion Leaders ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Financial Position and Capitalization ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Más contenido relacionado

La actualidad más candente

Global cancer immunotherapy market outlook 2020KuicK Research

Inovio Pharmaceuticals PresentationInovio Pharmaceuticals, Inc.

Quantum ImmunlogicsPro-Active Capital Resources Group

Global cancer immunotherapy market outlook 2020KuicK Research

Inovio - Corporate Presentation - July 2014Company Spotlight

Inovio Pharmaceuticals - Revolutionizing VaccinesCompany Spotlight

Taking Immunotherapy to the Next levelCompany Spotlight

Inmuno oncologyLuis Miguel Zetina Toache

Cancer immunomodulators market & pipeline insight 2020KuicK Research

Inovio Pharmaceuticals - October 2015Company Spotlight

Global dendritic cell cancer vaccine market outlook 2020KuicK Research

GenomeTrakr: Whole-Genome Sequencing for Food Safety and A New Way Forward in...ExternalEvents

Presentaiton inovio 314Company Spotlight

Inovio sep13presCompany Spotlight

SwaanUniversity of Maryland Baltimore

1810 3 q-2018-presentation-v7targovax2017

Download Global cancer immunotoxins market & clinical pipeline insight 2020KuicK Research

1711 3 q presentation v7 uten backuptargovax2017

Btp a poc nanotechnology company.pptxRaouf Guirguis

La actualidad más candente (19)

Global cancer immunotherapy market outlook 2020

Inovio Pharmaceuticals Presentation

Quantum Immunlogics

Global cancer immunotherapy market outlook 2020

Inovio - Corporate Presentation - July 2014

Inovio Pharmaceuticals - Revolutionizing Vaccines

Taking Immunotherapy to the Next level

Inmuno oncology

Cancer immunomodulators market & pipeline insight 2020

Inovio Pharmaceuticals - October 2015

Global dendritic cell cancer vaccine market outlook 2020

GenomeTrakr: Whole-Genome Sequencing for Food Safety and A New Way Forward in...

Presentaiton inovio 314

Inovio sep13pres

Swaan

1810 3 q-2018-presentation-v7

Download Global cancer immunotoxins market & clinical pipeline insight 2020

1711 3 q presentation v7 uten backup

Btp a poc nanotechnology company.pptx

Más de Chelli Miller

Can you stand out in the Sea of JP Morgan Healthcare Conference Suits?Chelli Miller

Swimming with the sharks in med schoolChelli Miller

Another Year of Top Residencies for SabaChelli Miller

Xchange reception @ JP Morgan Healthcare Conference Week!Chelli Miller

Exclusive mHealth Programming @ the AdaMed2014 ConferenceChelli Miller

AdvaMed2014 Invites mHealth to Chicago!Chelli Miller

DEVELOPMENT OF ESSENTIAL SAMPLE PREPARATION TECHNIQUES IN PROTEOMICS USING UL...Chelli Miller

Pharmatimes articleChelli Miller

Abviva, Inc. (PK ABVV) presentation OneMedForum-New YorkChelli Miller

Más de Chelli Miller (9)

Can you stand out in the Sea of JP Morgan Healthcare Conference Suits?

Swimming with the sharks in med school

Another Year of Top Residencies for Saba

Xchange reception @ JP Morgan Healthcare Conference Week!

Exclusive mHealth Programming @ the AdaMed2014 Conference

AdvaMed2014 Invites mHealth to Chicago!

DEVELOPMENT OF ESSENTIAL SAMPLE PREPARATION TECHNIQUES IN PROTEOMICS USING UL...

Pharmatimes article

Abviva, Inc. (PK ABVV) presentation OneMedForum-New York

Último

Ensure the security of your HCL environment by applying the Zero Trust princi...Roland Driesen

unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE AbudhabiAbortion pills in Kuwait Cytotec pills in Kuwait

Call Girls In Panjim North Goa 9971646499 Genuine Serviceritikaroy0888

Best VIP Call Girls Noida Sector 40 Call Me: 8448380779Delhi Call girls

A DAY IN THE LIFE OF A SALESMAN / WOMANIlamathiKannappan

Grateful 7 speech thanking everyone that has helped.pdfPaul Menig

Call Girls Jp Nagar Just Call 👗 7737669865 👗 Top Class Call Girl Service Bang...amitlee9823

RSA Conference Exhibitor List 2024 - Exhibitors DataExhibitors Data

Value Proposition canvas- Customer needs and painsP&CO

Call Girls in Gomti Nagar - 7388211116 - With room Servicediscovermytutordmt

Famous Olympic Siblings from the 21st Centuryrwgiffor

Insurers' journeys to build a mastery in the IoT usageMatteo Carbone

Call Girls In Holiday Inn Express Gurugram➥99902@11544 ( Best price)100% Genu...lizamodels9

Regression analysis: Simple Linear Regression Multiple Linear RegressionRavindra Nath Shukla

Unlocking the Secrets of Affiliate Marketing.pdfOnline Income Engine

Best Basmati Rice Manufacturers in IndiaShree Krishna Exports

HONOR Veterans Event Keynote by Michael HawkinsMichael W. Hawkins

0183760ssssssssssssssssssssssssssss00101011 (27).pdfRenandantas16

Yaroslav Rozhankivskyy: Три складові і три передумови максимальної продуктивн...Lviv Startup Club

Progress Report - Oracle Database Analyst SummitHolger Mueller

ImmunoCellular Investor Presentation

1. January 2010 Manish Singh, PhD President and CEO OTC BB: IMUC.OB www.imuc.com

6. ICT-107: Dendritic Cell-Based Vaccine Targeting Cancer Stem Cells and Tumor Associated Antigens January 2010 Antigens Tumor Expression CSC Expression gp100 Melanoma, brain cancer Trp-2 Melanoma and brain cancer High Her-2/neu Breast, ovarian cancer Medium MAGE-1 Melanoma, brain cancer AIM Breast, ovarian, colon, brain High IL-13aR2 Brain cancer

8. Summary of Clinical Data: Progression-Free and Overall Survival January 2010 SOC = Standard of care (surgery + radiation + Temozolomide) Newly Diagnosed (16) SOC + ICT-107 Historical Control (SOC) Median PFS (months) 19.0 6.9 Median OS (months) > 21 14.2 % Survival at 12 months 94% 60% % Survival at 21 months 80% 30% Recurrent (3) Median OS (months) 30.5 7.0 (9.2 with Avastin+SOC)

10.

11.

12.

13.

14.

15.

ImmunoCellular Investor Presentation

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (19)

Similar a ImmunoCellular Investor Presentation

Similar a ImmunoCellular Investor Presentation (20)

Más de Chelli Miller

Más de Chelli Miller (9)

Último

Último (20)

ImmunoCellular Investor Presentation